Activity of (1-benzyl-4-triazolyl)-indole-2-carboxamides against Toxoplasma gondii and Cryptosporidium parvum. (August 2022)
- Record Type:
- Journal Article
- Title:
- Activity of (1-benzyl-4-triazolyl)-indole-2-carboxamides against Toxoplasma gondii and Cryptosporidium parvum. (August 2022)
- Main Title:
- Activity of (1-benzyl-4-triazolyl)-indole-2-carboxamides against Toxoplasma gondii and Cryptosporidium parvum
- Authors:
- Khan, Shahbaz M.
Garcia Hernandez, Anolan
Allaie, Idrees Mehraj
Grooms, Gregory M.
Li, Kun
Witola, William H.
Stec, Jozef - Abstract:
- Abstract: Parasitic diseases such as toxoplasmosis and cryptosporidiosis remain serious global health challenges, not only to humans but also to domestic animals and wildlife. With only limited treatment options available, Toxoplasma gondii and Cryptosporidium parvum (the causative agents of toxoplasmosis and cryptosporidiosis, respectively) constitute a substantial health threat especially to young children and immunocompromised individuals. Herein, we report the synthesis and biological evaluation of a series of novel (1-benzyl-4-triazolyl)-indole-2-carboxamides and related compounds that show efficacy against T. gondii and C. parvum . Closely related analogs 7c (JS-2-30) and 7e (JS-2-44) showed low micromolar activity with IC50 indices ranging between 2.95 μM and 7.63 μM against both T. gondii and C. parvum, whereas the compound representing (1-adamantyl)-4-phenyl-triazole, 11b (JS-2-41), showed very good activity with an IC50 of 1.94 μM, and good selectivity against T. gondii in vitro . Importantly, compounds JS-2-41 and JS-2-44 showed appreciable in vivo efficacy in decreasing the number of T. gondii cysts in the brains of Brown Norway rats . Together, these results indicate that (1-benzyl-4-triazolyl)-indole-2-carboxamides and (1-adamantyl)-4-phenyl-triazoles are potential hits for medicinal chemistry explorations in search for novel antiparasitic agents for effective treatment of cryptosporidiosis and toxoplasmosis. Graphical abstract: Image 1 Highlights:Abstract: Parasitic diseases such as toxoplasmosis and cryptosporidiosis remain serious global health challenges, not only to humans but also to domestic animals and wildlife. With only limited treatment options available, Toxoplasma gondii and Cryptosporidium parvum (the causative agents of toxoplasmosis and cryptosporidiosis, respectively) constitute a substantial health threat especially to young children and immunocompromised individuals. Herein, we report the synthesis and biological evaluation of a series of novel (1-benzyl-4-triazolyl)-indole-2-carboxamides and related compounds that show efficacy against T. gondii and C. parvum . Closely related analogs 7c (JS-2-30) and 7e (JS-2-44) showed low micromolar activity with IC50 indices ranging between 2.95 μM and 7.63 μM against both T. gondii and C. parvum, whereas the compound representing (1-adamantyl)-4-phenyl-triazole, 11b (JS-2-41), showed very good activity with an IC50 of 1.94 μM, and good selectivity against T. gondii in vitro . Importantly, compounds JS-2-41 and JS-2-44 showed appreciable in vivo efficacy in decreasing the number of T. gondii cysts in the brains of Brown Norway rats . Together, these results indicate that (1-benzyl-4-triazolyl)-indole-2-carboxamides and (1-adamantyl)-4-phenyl-triazoles are potential hits for medicinal chemistry explorations in search for novel antiparasitic agents for effective treatment of cryptosporidiosis and toxoplasmosis. Graphical abstract: Image 1 Highlights: (1-Benzyl-4-triazolyl)-indole-2-carboxamide show interesting antiparasitic activity. Compounds' concentrations of 1.94–7.63 μM inhibited growth of T. gondii & C. parvum . The best hits displayed in vivo efficacy comparable to the standard drug atovaquone. Those compounds show good potential for further development as antiparasitic agents. … (more)
- Is Part Of:
- International journal for parasitology. Volume 19(2022)
- Journal:
- International journal for parasitology
- Issue:
- Volume 19(2022)
- Issue Display:
- Volume 19, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 19
- Issue:
- 2022
- Issue Sort Value:
- 2022-0019-2022-0000
- Page Start:
- 6
- Page End:
- 20
- Publication Date:
- 2022-08
- Subjects:
- Toxoplasma gondii -- Cryptosporidium parvum -- Antiprotozoal agents -- Drug discovery -- (1-Benzyl-4-triazolyl)-indole-2-carboxamides -- (1-adamantyl)-4-phenyl-triazoles
Parasitic diseases -- Chemotherapy -- Periodicals
Drug resistance -- Periodicals
616.96061 - Journal URLs:
- http://www.elsevier.com/journals ↗
- DOI:
- 10.1016/j.ijpddr.2022.04.001 ↗
- Languages:
- English
- ISSNs:
- 2211-3207
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22659.xml